Once More Into the Breach: Lilly Plans New Phase 3 Study of Anti-Amyloid MAb in Alzheimer’s
Despite tepid phase 3 results (see here and here), Lilly will continue late-phase development of its anti-amyloid MAb, solanezumab, in patients with mild AD. Today’s company press release says that the new trial will begin “no later than Q3 2013.” Market analysts expect the trial to complete in 2015 (the anticipated length of the trial is presumably the same as that of Lilly’s EXPEDITION studies, 18 months). If successful, the drug would launch in 2017.
Now set the teeth and stretch the nostril wide,
Hold hard the breath and bend up every spirit
To his full height.